DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Alkem Laboratories Limited (ALKEM) share price today?

Alkem Laboratories Limited (ALKEM) is trading at ₹5,050 on the NSE, down 1.38% on the day. Source: DocStoX.

What is the PE ratio of Alkem Laboratories Limited?

Alkem Laboratories Limited has a price-to-earnings (PE) ratio of 26.2 in the Healthcare sector.

What is the market capitalisation of Alkem Laboratories Limited?

Alkem Laboratories Limited has a market capitalisation of approximately ₹60,435 crore.

Is Alkem Laboratories Limited a profitable company?

Alkem Laboratories Limited generates a return on equity of 16.7% with a net profit margin of 16.0%. That is a reasonable return on shareholder capital.

What is the 52-week high and low of ALKEM?

Alkem Laboratories Limited (ALKEM) has traded between ₹5,042 and ₹5,933.5 over the past 52 weeks, against a current price of ₹5,050.

Does Alkem Laboratories Limited pay a dividend?

Yes. Alkem Laboratories Limited currently offers a dividend yield of 1.03%. Dividend payments depend on the board's declaration each year.

Alkem Laboratories Limited

F&O

₹5,050.00▼ -70.50 (-1.38%)

ALKEM·NSE·Healthcare

Market Cap

60435.32 Cr

PE Ratio

26.23

Volume

1,60,778

Day High - Low

5147.00 - 5042.00

52W High-Low

5933.50 - 5042.00

₹5,050.00▼ -70.50 (-1.38%)

Market Cap60435.32 Cr

PE Ratio26.23

Volume1,60,778

Day High - Low5147.00 - 5042.00

52W High-Low5933.50 - 5042.00

Alkem Laboratories Limited (ALKEM): company summary

Annual revenue rose 13.5% to ₹14,712 crore, while annual net profit rose 6.1% to ₹2,351 crore.

Alkem Laboratories Limited (ALKEM) is a mid-cap Healthcare company valued at ₹60,435 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Alkem Laboratories Limited last traded at ₹5,050, modestly down 1.38% on the day.
Recent developments: On 2026-09-16, Alkem Laboratories launched NeuCeno, a once-daily oral therapy for partial-onset seizures in adults, available in five strengths. Clinical studies showed reductions in seizure frequency among adults with uncontrolled focal seizures.
Financial performance: Annual revenue rose 13.5% to ₹14,712 crore, while annual net profit rose 6.1% to ₹2,351 crore. The latest quarter saw revenue rise 11.0% year-on-year to ₹3,740 crore, but net profit fell 22.0% to ₹521 crore, reflecting a widening gap between revenue growth and profit growth.
Valuation multiples: The stock trades at 26.2 times earnings, a discount to the Healthcare median of 32.0, 4.42 times book value. It yields 1.0%.
Things to watch: The company's net profit margin fell 1.1 percentage points to 16.0%, and the latest quarter's net profit dropped 22.0% year-on-year. The stock is 11.0% below its 52-week high, and promoter holding fell by 1.50 percentage points in the quarter.
Where it stands: Alkem Laboratories reported annual revenue growth of 13.5% and net profit growth of 6.1%, but the latest quarter's net profit fell 22.0% year-on-year. The stock is 11.0% below its 52-week high, and promoter holding decreased by 1.50 percentage points.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.1/10

Weak

Fair Value

ROE

16.66%

Strong

P/E

26.23x

Fair

Debt / Equity

0.15

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY MIDCAP 150NIFTY PHARMA

Day₹5042

₹5147

52W₹5042

₹5934

DocStoX take

Supported by risk (9.8) and quality (6.8), but held back by momentum (0.0). Risk looks strong at 9.8, but that is offset by momentum at 0.0 and valuation at 2.8. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.1

/10

Weak

Quality

Solid

ROE 16.7%

Valuation

Expensive

P/E 26.2×

Growth

Slow

Revenue +10.7% 5Y CAGR

Risk

Low risk

D/E 0.15

Momentum

Weak

1% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹5,050

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹60,435 Cr

52W High / Low

₹5934 / ₹5042

Dividend Yield

1.03%

Promoter Holding

49.70%

EPS (TTM)

₹192.51

Book Value

₹1156.01

Key highlights

Low leverage — D/E 0.15
Profitable in all of the last 5 years
Healthy net margin (16%)
Momentum is weak (0.0/10)
Near the bottom of its 52-week range (1%)

3 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Alkem Laboratories Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Alkem Laboratories Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Alkem Laboratories Limited with peers

Alkem Laboratories Limited vs Sun Pharmaceutical Industries Limited Alkem Laboratories Limited vs Divi's Laboratories Limited Alkem Laboratories Limited vs Torrent Pharmaceuticals Limited Alkem Laboratories Limited vs Apollo Hospitals Enterprise Limited Alkem Laboratories Limited vs Zydus Lifesciences Limited Alkem Laboratories Limited vs Laurus Labs Limited

Related tools & concepts

Value Alkem Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

ALKEM newsLatest coverage & filings Open screenerFilter the whole market